rohtas's picture
hedwigai harness-model benchmark v2: 180 graded units, 195 runs, docs, traces, keys, grades
a01096a verified
Raw History Blame Contribute Delete
8.34 kB
{
"task": "T02 FDA CDER novel approvals Sept 2026",
"expected_count": 9,
"scoring": {
"row_correct_if": "brand + active ingredient + date exact; indication substantively matches",
"note": "The FDA page lists rows newest-first; Emcitate is row 45 and sits in a transposed block the `fda approvals` program dropped in the pilot (bugs.md #1). openFDA shows exactly 9 ORIG approvals with class 'Type 1 - New Molecular Entity' in Sept 2026, matching the page. Excluded on purpose: Type 2/5 NDAs (Lamlique, Bexlutry, Omcazio, Zueino, Degevma) and BLA Garzulys (no NME class) — not on CDER's novel list."
},
"rows": [
{
"brand": "Zanvastro",
"active ingredient": "zilganersen",
"approved on": "2026-09-03",
"approved to treat": "Alexander disease in pediatric and adult patients",
"application": "NDA220210",
"sponsor": "Ionis",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 37: Zanvastro | zilganersen | 9/3/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ZANVASTRO%22",
"quote": "NDA220210 ... submission_type ORIG, submission_status AP, submission_status_date 20260903, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
},
{
"brand": "Etcamah",
"active ingredient": "camizestrant",
"approved on": "2026-09-04",
"approved to treat": "HR-positive, HER2-negative (ESR1-mutated) locally advanced or metastatic breast cancer",
"application": "NDA220359",
"sponsor": "AstraZeneca",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 38: Etcamah | camizestrant | 9/4/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ETCAMAH%22",
"quote": "NDA220359 ... submission_type ORIG, submission_status AP, submission_status_date 20260904, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
},
{
"brand": "Isembyld",
"active ingredient": "apitegromab-mstn",
"approved on": "2026-09-11",
"approved to treat": "spinal muscular atrophy in adults and pediatric patients 2 years and older",
"application": "BLA761463",
"sponsor": "Scholar Rock",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 39: Isembyld | apitegromab-mstn | 9/11/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ISEMBYLD%22",
"quote": "BLA761463 ... submission_type ORIG, submission_status AP, submission_status_date 20260911, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
},
{
"brand": "Pixclara",
"active ingredient": "floretyrosine F 18",
"approved on": "2026-09-11",
"approved to treat": "PET imaging to differentiate recurrent or progressive glioma from treatment-related change",
"application": "NDA218592",
"sponsor": "Telix",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 40: Pixclara | floretyrosine F 18 | 9/11/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22PIXCLARA%22",
"quote": "NDA218592 ... submission_type ORIG, submission_status AP, submission_status_date 20260911, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
},
{
"brand": "Onswik",
"active ingredient": "insulin efsitora alfa-gobe",
"approved on": "2026-09-23",
"approved to treat": "glycemic control in adults with type 2 diabetes mellitus",
"application": "BLA761408",
"sponsor": "Eli Lilly",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 41: Onswik | insulin efsitora alfa-gobe | 9/23/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ONSWIK%22",
"quote": "BLA761408 ... submission_type ORIG, submission_status AP, submission_status_date 20260923, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
},
{
"brand": "Lyrfigtu",
"active ingredient": "lirafugratinib",
"approved on": "2026-09-23",
"approved to treat": "previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 alteration",
"application": "NDA220425",
"sponsor": "Elevar",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 42: Lyrfigtu | lirafugratinib | 9/23/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22LYRFIGTU%22",
"quote": "NDA220425 ... submission_type ORIG, submission_status AP, submission_status_date 20260923, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
},
{
"brand": "Juvmo",
"active ingredient": "tavapadon",
"approved on": "2026-09-25",
"approved to treat": "Parkinson's disease in adults",
"application": "NDA220415",
"sponsor": "AbbVie",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 43: Juvmo | tavapadon | 9/25/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22JUVMO%22",
"quote": "NDA220415 ... submission_type ORIG, submission_status AP, submission_status_date 20260925, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
},
{
"brand": "Atebrioz",
"active ingredient": "zilurgisertib",
"approved on": "2026-09-25",
"approved to treat": "reduce new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP), adults and pediatric patients 12+",
"application": "NDA221198",
"sponsor": "Mirum",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 44: Atebrioz | zilurgisertib | 9/25/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ATEBRIOZ%22",
"quote": "NDA221198 ... submission_type ORIG, submission_status AP, submission_status_date 20260925, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
},
{
"brand": "Emcitate",
"active ingredient": "tiratricol",
"approved on": "2026-09-28",
"approved to treat": "peripheral thyrotoxicosis in patients with MCT8 deficiency",
"application": "NDA220963",
"sponsor": "Rare Thyroid",
"sources": [
{
"kind": "primary",
"url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",
"quote": "Row 45: Emcitate | tiratricol | 9/28/2026"
},
{
"kind": "other",
"url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22EMCITATE%22",
"quote": "NDA220963 ... submission_type ORIG, submission_status AP, submission_status_date 20260928, submission_class_code_description 'Type 1 - New Molecular Entity'"
}
]
}
],
"frozen": "2026-11-12"
}